Danhong Injection in the Treatment of Acute Ischemic Stroke
NCT ID: NCT01677208
Last Updated: 2022-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1503 participants
INTERVENTIONAL
2013-03-13
2019-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke
NCT02152280
An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke
NCT04952064
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
NCT02430350
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
NCT05700097
Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke
NCT04950790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Danhong injection
Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
Danhong injection
A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Standard medical care
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
placebo
Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
Standard medical care
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
placebo
0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Danhong injection
A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Standard medical care
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
placebo
0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 18 - 70 years.
* Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage.
* Clinical diagnosis of "Xueyu Zheng" (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of "Xueyu Zheng" in ischemic stroke ≥ 20. The Chinese medicine symptoms scales of "Xueyu Zheng" is defined as following (1)hemiplegia-10,(2)numbness of limbs-10，(3) dark face-9,(4)purple or dark lip-8,(5)Roughness of skin-4, (6) pain with fixed point-5, (7) purple or dark tongue-10,(8)ecchymosis on tongue-10,(9)purple sublingual vessel-10,(10)varicose sublingual vessel-8,(11)unsmooth pulse-8,(12)intermittent pulse-1.
* Onset of symptoms in 1 week prior to initiation of administration of study drug.
* Clinical diagnosis of cerebral anterior circulation obstruction.
* 4≤NIHSS\<20.
* Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating centers.
Exclusion Criteria
* Patients with thrombolysis or endovascular treatment.
* Known history of allergy or suspected allergic to the drug.
* Blood glucose 2.8 or \> 16.8 mmol / l under the treatment of diabetes or with severe complications due to diabetes (eg. peripheral neuropathy, diabetic gangrene).
* Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.
* Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value.
* Severe cardiac dysfunction on echocardiogram or the grade of heart function over Ⅲ grade.
* History of prior stroke with mRS ≥2.
* Complicated with atrial fibrillation.
* Severe stroke as assessed by appropriate imaging techniques (eg. massive cerebral infarction including more than one lobe of brain or over 1/3 of blood-supply area of middle cerebral artery).
* Prior disable patients.
* Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.
* Suspected addicted into alcohol or drug abuse.
* With severe complications that would make the condition more complicated assessed by the investigator.
* Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months.
* Woman who is under menstrual period.
* Patient who is participating in other trials or has been participated in other trials in recent 3 months.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Food and Drug Administration
OTHER_GOV
China Academy of Chinese Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhong Wang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhong Wang, Professor
Role: PRINCIPAL_INVESTIGATOR
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Xing-quan Zhao, Professor
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Yong-yan Wang, Professor
Role: STUDY_CHAIR
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Xiao-xi Du, Professor
Role: STUDY_DIRECTOR
China Food and Drug Administration
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Artillery General Hospital of Chinese People's Liberation Army
Beijing, Beijing Municipality, China
Xinqiao Hospital of Third Military Medical University
Chongqing, Chongqing Municipality, China
Chongqing Three Gorges Central Hospital
Chongqing, Chongqing Municipality, China
Guangdong No.2 Provincial People's Hospital
Guangzhou, Guangdong, China
Guangzhou hospital of integrated Chinese and Western medicine
Guangzhou, Guangdong, China
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, China
The Second Central Hospital of Baoding City
Baoding, Hebei, China
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China
Handan Central Hospital
Handan, Hebei, China
The Second Affiliated Hopital of Harbin Medical University
Harbin, Helongjiang, China
The Second Chinese Medical Hospital of Luoyang City
Luoyang, Henan, China
Nanyang T.C.M. Hospital
Nanyang, Henan, China
Nanshi Hospital of Nanyang
Nanyang, Henan, China
The First Affiliated Hospital of Henan University of T.C.M.
Zhengzhou, Henan, China
People's Hospital of Zhengzhou
Zhengzhou, Henan, China
Zhengzhou NO.7 People's Hospital
Zhengzhou, Henan, China
Zhoukou Hospital of T.C.M.
Zhoukou, Henan, China
The Central Hospital of Wuhan
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Zhongshan Hospital of Hubei Province
Wuhan, Hubei, China
Fifth Hospital in Wuhan
Wuhan, Hubei, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Tianyou Hospital Affiliated to Wuhan University of Science & Technology
Wuhan, Hubei, China
Huangpi District Hospital of T.C.M.
Wuhan, Hubei, China
Changsha Central Hospital
Changsha, Hunan, China
The First Hospital of Changsha
Changsha, Hunan, China
The second people's hospital of Hunan Province
Changsha, Hunan, China
Xiangya Hospital Central-south University
Changsha, Hunan, China
Nanjing Hospital of T.C.M.
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Jilin Province People's Hospital
Changchun, Jilin, China
The Affiliated Hopital to Changchun University of Chinese Medicine
Changchun, Jilin, China
The First Hospital Affiliated to Jilin University
Changchun, Jilin, China
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Liaoyuan Traditional Chinese Medical Hospital
Liaoyuan, Jilin, China
Anshan Central Hospital
Anshan, Liaoning, China
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China
Dandong First Hospital
Dandong, Liaoning, China
Panjin Central Hospital
Panjin, Liaoning, China
People's Liberation Army No.202 Hospital
Shenyang, Liaoning, China
The General Hospital of Shenyang Military
Shenyang, Liaoning, China
People's Liberation Army No.463 Hospital
Shenyang, Liaoning, China
Affiliated Hospital of Chifeng University
Chifeng, Neimenggu, China
Fenyang Hospital of Shanxi Province
Lüliang, Shanxi, China
The Second Affiliated Hospital to Shanxi Medical University
Taiyuan, Shanxi, China
Affiliated Hospital of Shanxi University of Chinese Medicine
Xianyang, Shanxi, China
The Second Affiliated Hospital of Shanxi University of T.C.M.
Xianyang, Shanxi, China
Shanxi Province Hospital of T.C.M.
Xi’an, Shanxi, China
The PLA Fourth Fifty-one Hospital
Xi’an, Shanxi, China
Shanxi Provincial People's Hospital
Xi’an, Shanxi, China
Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Chengdu, Sichuan, China
The First Affiliated Hopital of Chengdu Medical College
Chengdu, Sichuan, China
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Tianjin, Tianjin Municipality, China
Xin Hua Hospital of Zhejiang Province
Hangzhou, Zhejiang, China
Zhejiang Provincial Hospital of T.C.M.
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Huzhou Central Hospital
Huzhou, Zhejiang, China
Peking University First Hospital
Beijing, , China
Tiantan Hospital Affiliated to Capital Medical University
Beijing, , China
Xuan Wu Hospital Affiliated to Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Li B, Wang Y, Lu J, Liu J, Yuan Y, Yu Y, Wang P, Zhao X, Wang Z. Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial. Trials. 2015 Dec 9;16:561. doi: 10.1186/s13063-015-1076-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DH20120423
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.